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Abstract
Background: The short arm of human chromosome 3 is involved in the development of many cancers including
lung cancer. Three bona fide lung cancer tumor suppressor genes namely RBSP3 (AP20 region),NPRL2 and RASSF1A
(LUCA region) were identified in the 3p21.3 region. We have shown previously that homozygous deletions in AP20
and LUCA sub-regions often occurred in the same tumor (P < 10
-6).
Methods: We estimated the quantity of RBSP3, NPRL2, RASSF1A, GAPDH, RPN1 mRNA and RBSP3 DNA copy number
in 59 primary non-small cell lung cancers, including 41 squamous cell and 18 adenocarcinomas by real-time
reverse transcription-polymerase chain reaction based on TaqMan technology and relative quantification.
Results: We evaluated the relationship between mRNA level and clinicopathologic characteristics in non-small cell
lung cancer. A significant expression decrease (≥2) was found for all three genes early in tumor development: in
85% of cases for RBSP3; 73% for NPRL2 and 67% for RASSF1A (P < 0.001), more strongly pronounced in squamous
cell than in adenocarcinomas. Strong suppression of both, NPRL2 and RBSP3 was seen in 100% of cases already at
Stage I of squamous cell carcinomas. Deregulation of RASSF1A correlated with tumor progression of squamous cell
(P = 0.196) and adenocarcinomas (P < 0.05). Most likely, genetic and epigenetic mechanisms might be responsible
for transcriptional inactivation of RBSP3 in non-small cell lung cancers as promoter methylation of RBSP3 according
to NotI microarrays data was detected in 80% of squamous cell and in 38% of adenocarcinomas. With NotI
microarrays we tested how often LUCA (NPRL2, RASSF1A) and AP20 (RBSP3) regions were deleted or methylated in
the same tumor sample and found that this occured in 39% of all studied samples (P < 0.05).
Conclusion: Our data support the hypothesis that these TSG are involved in tumorigenesis of NSCLC. Both genetic
and epigenetic mechanisms contribute to down-regulation of these three genes representing two tumor
suppressor clusters in 3p21.3. Most importantly expression of RBSP3, NPRL2 and RASSF1A was simultaneously
decreased in the same sample of primary NSCLC: in 39% of cases all these three genes showed reduced
expression (P < 0.05).
Background
The short arm of human chromosome 3 (region 3p21.3)
contains clusters of tumor suppressor genes (TSG)
involved in multiple cancer types including lung, kidney,
breast, cervical, nasopharyngeal and other carcinomas
[1-5]. We performed a comprehensive deletion survey of
3p in more than 400 of major epithelial cancer samples
and identified two most frequently affected regions -
LUCA at the centromeric and AP20 at the telomeric
border of 3p21.3 [6-10]. Aberrations in these loci were
detected in more than 90% of studied tumors. Homozy-
gous deletions (HD) were frequently detected in all
tumors in both the LUCA and AP20 regions. The fre-
quent chromosome losses in these regions suggested
that they harbor several multiple TSG [9,10]. More than
20 genes were localized in these two regions and among
them at least three TSG were identified: RBSP3
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gene or HYA22 or CTDSPL; CTD small phosphatase
family), NPRL2 (nitrogen permease regulator-like 2 gene
or G21 or TUSC4; NPR family) and RASSF1A (Ras asso-
ciation domain family member 1 gene). RBSP3 was
mapped to AP20 and the others two to the LUCA
region [1,11-13].
The RBSP3 gene occupies more than 120 kb and con-
tains at least 8 exons coding for a 4.8 kb mRNA that is
ubiquitously expressed in normal tissues including lung.
By sequence analysis RBSP3 belongs to a gene family of
small C-terminal domain phosphatases that may control
the RNA polymerase II transcription machinery [14].
Two sequence splice variants of RBSP3 ( Aa n dB )w e r e
identified and an initial analysis of RBSP3 was per-
formed in lung and other cancers [12]. The expression
of the gene was greatly decreased in several small cell
lung cancer (SCLC) and NSCLC cell lines. RBSP3
showed growth suppression with regulated transgenes in
cell culture and suppression of tumor formation in
SCID mice. It was demonstrated that transient expres-
sion of variant A and B resulted in drastic reduction of
the phosphorylated form of RB protein presumably lead-
ing to a block of the cell cycle at the G1/S boundary. In
addition, frameshift, nonsense and missense mutations
in RBSP3 have been reported [15]. All these features are
consistent with classical characteristics of a TSG.
The NPRL2/G21 gene covers 3.3 kb and contains 11
exons coding for the main 1.8 kb transcript with multi-
ple splice isoforms that are expressed in all tested nor-
mal tissues including lung. By sequence analysis, the
main product of NPRL2/G21 encodes a soluble protein
that has a bipartite nuclear localization signal, a protein-
binding domain, similarity to MutS core domain, and a
newly identified nitrogen permease regulator 2 domain
with unknown function. This information suggests that
the nuclear protein NPRL2/G21 may be involved in
DNA mismatch repair, cell cycle checkpoint signaling,
and regulation of the apoptotic pathway. NPRL2 plays
an important role in cisplatin-induced resistance in
human non-small-cell lung cancer cells [16,17]. Pre-
viously obtained results indicated that NPRL2/G21 is a
multiple tumor suppressor gene [16,18,19].
The RASSF1 gene occupies 7.6 kb and contains 5
exons coding for 2 kb alternatively spliced mRNAs
[6,11,20]. One of the major splicing forms is RASSF1A.
Several studies have shown that loss of RASSF1A
expression occurs in many different cancers because of
tumor acquired promoter DNA methylation and the
gene is able to suppress growth of lung cancer cells in
culture and tumor formation in mice [13,21-24]. For
example, RASSF1A is silenced by promoter hypermethy-
lation in 100% of SCLCs and in 63% of NSCLCs cell
lines and in 50-100% SCLC and 21-58% NSCLC primary
tumors [25-28]. As in the case of RBSP3, frameshift,
nonsense and missense mutations in RASSF1A have
been discovered [15,29]. The amino acid sequence of
RASSF1A (340 amino acids) contains a predicted diacyl-
glycerol (DAG) binding domain and a Ras association
domain. Association of human proteins RASSF1C and
RASSF1A with Ras protein was demonstrated [30,31].
RASSF1A can induce cell-cycle arrest by engaging the
Rb-family cell cycle checkpoint [32]. RASSF1A is
involved in several growth regulating and apoptotic
pathways and regulates cell proliferation, cellular integ-
rity and cell death [24,27]. These and other results
strongly suggest that RASSF1A is an important human
TSG involved in the development or progression of
many epithelial tumors.
Previously only few studies were performed to com-
pare expression of several3 pT S Gi nt h es a m et u m o r
sample [33,34]. To investigate this further we chose
RBSP3, NPRL2 and RASSF1A and analyzed their expres-
sion by qPCR in primary tumors: non-small cell lung
cancer (NSCLC) - adenocarcinoma (AC) and squamous
cell lung cancer (SCC).
For the first time we found that expression of all three
genes was significantly decreased in 67-85% of tested
NSCLC cases. Moreover, the simultaneous down-regula-
tion of RBSP3, NPRL2 and RASSF1A in the same tumor
sample was observed in 39% of all cases. Both genetic
and epigenetic mechanisms contributed to deregulation
of these three genes representing two TSG clusters in
3p21.3.
Methods
Tissue specimens
Paired specimens of non-small cell lung cancer (NSCLC)
tissues including 41 squamous cell carcinomas (SCC), 18
adenocarcinomas AC) and adjacent morphologically nor-
mal tissues (conventional “normal” matched control sam-
ples) were obtained after surgical resection of primary
lung cancer prior radiation or chemotherapy and stored
in liquid nitrogen. “Normal” matched controls were
obtained minimum at 2 cm distance from the tumor and
confirmed histologically as normal lung epithelial cells.
The diagnosis was verified by histopathology and only
samples containing 70% or more tumor cells were used
in the study. The samples were collected in accordance
to the guidelines issued by the Ethics Committee of
Blokhin Cancer Research Center, Russian Academy of
Medical Sciences (Moscow). All patients gave written
informed consent that is available upon request. The
study was done in accordance with the principles out-
lined in the Declaration of Helsinki. All tumor specimens
were characterized according to the International System
of Clinico-Morphological Classification of Tumors
(TNM), based on the tumor-node-metastasis and staging
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tion of 1999 [36]. Relevant clinical and pathological char-
acteristics of the patients with NSCLC included in this
study are summarized in Table 1. Normal lung tissues
(autopsy material) were obtained post mortally from ten
healthy individuals (age 23-49 lacking cancer history with
absence of chronic diseases).
DNA and total RNA extraction and reverse
transcription reaction
DNA was extracted using the Dneasy Tissue kit
(Qiagen, USA) and total RNA was isolated with Rneasy
mini kit (Qiagen, USA) according to the manufacturer’s
recommendation. RNA quality was assessed with
spectrophotometer NanoDrop ND-1000 (NanoDrop
Technologies Inc. USA) and by gel electrophoresis. All
RNA samples were treated with RNAse free DNase I
(Fermentas, Lithuania) and cDNA was synthesized using
MMLV reverse transcriptase and random hexamers
according to standard manufacturer’s protocol (Fermen-
tas, Lithuania).
Analysis of mRNA and DNA copy number by qPCR
The sequences of primers and probes are shown in
Table 2. All reactions were performed using ABI 7000
PRISM™ SDS (Applied Biosystems) with RQ software
(PCR program: 10 min at 95°C, then 40 two-step cycles
15 s at 95°C and 60 s at 60°C) in total volume 25 μli n
triplicate. All probes contained the dye FAM at 5’-end
and RTQ1 at 3’-end. Final concentrations of primers
and probes for target and reference genes were:
RBSP3 cDNA primers- 350 nM, probe - 150 nM; RBSP3
DNA primers - 150 nM, probe - 100 nM; ACTB DNA
primers- 200 nM, probe - 100 nM, NPRL2 cDNA pri-
mers - 500 nM, probe 300 nM; RASSF1A cDNA primers
- 300 nM, probe 300 nM;GAPDH cDNA primers - 300
nM, probe - 150 nM; RPN1 cDNA primers - 350 nM,
probe - 200 nM;RPN1 DNA primers - 200 nM, probe -
100 nM; GUSB cDNA primers - 350 nM, probe - 250
nM; GUSB DNA primers - 200 nM, probe - 200 nM.
PCR products were analyzed in 1.8% agarose gels and
nucleotide sequences of the amplicons were verified by
sequencing with 3730 DNA Analyzer automated
sequencer (Applied Biosystems).
qPCR data were analyzed using the relative quantifica-
tion or ΔΔCt-method [37,38] based on mRNA (or
DNA) copy number ratio (R) of a target gene versus
reference gene in a given tumor sample relative to
matched normal control sample (see above Tissue speci-
mens section) according to the formula:
R
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where E - efficiency of reaction, CT - threshold cycle,
ref - reference gene, tar - target gene.
All preliminary validation steps have been done:
standardization of all assays, reproducibility of the
qPCRs in parallel and in independent runs, selection of
reference samples and testing of reference genes
http://www.gene-quantification.info/.
NotI-microarray analysis
Microarrays were constructed essentially as previously
described [39,40]. In brief, two oligonucleotides:
NotX: 5’-AAAAGAATGTCAGTGTGTCACGTAT
GGACGAATTCGC-3’
and NotY: 5’-GGCCGCGAATTCGTCGGTATGC
ACTGTGTGTGACATTCAAA-3”
were used to create the NotI linker. Annealing was
carried out in a final volume of 100 μl containing 20 μl
of 100 μM NotX, 20 μl of 100 μM NotY, 10 μl of 10×M
buffer (Roche Molecular Biochemicals) and 50 μlo f
H2O. Two micrograms of tumor and normal control
DNA (50 μg/ml) were digested with 20 U of Sau3A
(Roche Molecular Biochemicals) at 37°C for 5 h and
then 0.4 μg of the digested DNAs were circularized
overnight with the T4 DNA ligase (Roche Molecular
Biochemicals) in the appropriate buffer in 1 ml reaction
mixture. Then DNA was concentrated with ethanol,
partially filled in and digested with 10 U of NotI at 37°C
for 3 h. Following digestion, NotI was heat inactivated
and DNAs were ligated overnight in the presence of a
50 M excess of NotI linker at room temperature. NotI-
representation (NR) probes were labeled in a PCR
Table 1 Clinical and pathological characteristics of
patients with NSCLC
Variables Patients
Gender/n Female/7, Male/52
Age Mean 60
Range 31-76
TNM/Stage Histological type of NSCLC
SCC AC
T1N0M0/Stage IA 6 5
T2N0M0/Stage IB 5 2
T3N0M0,T 2N1M0/Stage IIB 19 5
T1N2M0,T 2N2M0,T 3N1M0,T 3N2M0/Stage IIIA 11 5
T4N0M0/Stage IIIB – 1
N0 Stage (no metastases) 24 10
N1 Stage +N2 Stage (with metastases) 17 8
Central cancer 27 1
Peripheral cancer 9 16
ND 5 1
Total 41 18
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the DNA amplification step were in the 0.2-1.0 kb
range. Repeated PCR was conducted for labeling NR
with fluorophores.
Hybridization of coupled normal/tumor NotI samples
was carried out at 42°C for 15 h in a Lucidea Base device
(Amersham Pharmacia Biotech) according to manufac-
turer’s recommendations. Automatic washing of the
microarrays was performed in the same device using
manufacturer’s protocol. The following solutions were
sequentially used for the washing: 1) 0.2% SDS+1 SSC; 2)
0.2% SDS+0.1 SSC; 3) 0.1 SSC; 4) de-ionized water; 5)
isopropyl alcohol. Then microarrays were scanned in the
GenePix 4000 A and results were processed with Gene-
Pix Pro 6.0 software (Amersham Pharmacia Biotech).
Statistical analysis
Nonparametric Wilcoxon test was used to compare
mRNA expression differences of target and reference
g e n e sf o rt h es a m eN S C L Cs a m p l e .T h e ng r o u p so f
samples were compared in respect to average level of
mRNA decrease (LDav) and the frequency of decrease
(FD). The LD was calculated as 1/R and reflects the
n-fold factor by which the mRNA content decreased in
the tumor compared to normal tissue. Nonparametric
Kruskal-Wallis and Mann-Whitney rank-sum tests were
used to test mRNA differences (both LDav and FD) for
each target gene in NSCLC (AC, SCC) and with and
without metastases. Nonparametric Spearmen’s criterion
was used to calculate the coefficient of correlation
between the levels of mRNA decrease (LDav)f o re a c h
Table 2 Primers and probes for target and reference genes for expression levels and copy number studies
Gene Name Primers (F, R) and probe (Z)
sequences 5’ ! 3’
Amplicon
lengh
Target genes
RBSP3/CTDSPL
NM_001008392
RBSP3 (RB1 serine phosphatase from human
chromosome 3), CTD (carboxy-terminal domain,
RNA polymerase II, polypeptide A)
small phosphatase-like
cDNA
F: GCGAGAAAGCCTCCCAGTG
R: CCACCATTCTCCTCCACCAGT
Z: CCACATTGTAATCACGGAAGCAGCAGA
154
DNA
F: CAGAGTGCGTGTGCCGACT
R: ACAACTTCTCTGCGGGCGT
Z: CTGGCGGAGAGACTGGGAGCGA
126
NPRL2/G21
NM_006545
Nitrogen permease regulator-like 2 gene cDNA
F: GGACCTCACTACACAACAAATCCTG
R: GTCACAACGCCGTAGTACAGCA
Z: ACATCCAGAAGATTTCAGCAGAGGCAGAT
134
RASSF1A
NM_007182
Ras association (RalGDS/AF-6) domain family 1 cDNA
F: CGCGCATTGCAAGTTCAC
R: AGGCTCGTCCACGTTCGT
Z: CGCTCGTCTGCCTGGACTGTTGC
120
Reference genes
RPN1
NM_002950
Ribophorin I cDNA
F: CACCCTCAACAGTGGCAAGAAG
R: TGCATTTCGCTCACTCTGTCG
Z: CCCTCTGTCTTCAGCCTGGACTGC
125
DNA
F: TATGGGCCTTTCAGAGATGTGCCT
R: ACCACCCAAGCCTATCAACCAGTA
Z: TGGAGTCCAGCCCATCCCTGTCTGCTTCA
120
GUSB
NM_000181
Glucuronidase, beta
b-D-glucuronidase
cDNA
F: GATGGAAGAAGTGGTGCGTAGG
R: TTAGAGTTGCTCACAAAGGTCACAG
Z: CGTCCCACCTAGAATCTGCTGGCTACTACTT
171
DNA
F: TGCCGTGAGTCTCTGCTGTG
R: CCTACGCACCACTTCTTCCATC
Z: TGACCCTCTGTCCCTTCCCTCCTG
151
ACTB
NM_001101
Actin, ß DNA
F: GTGCTCAGGGCTTCTTGTCCTTT
R: TTTCTCCATGTCGTCCCAGTTGGT
Z: AAGGATTCCTATGTGGGCGACGAGGCCCA
160
GAPDH
NM_002046
Glyceraldehyde-3-phosphate dehydrogenase cDNA
F: GGAGTCAACGGATTTGGTC
R: TGGGTGGAATCATATTGGAACAT
Z: CCTTCATTGACCTCAACTACATGGTTTACAT
139
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ered statistically significant. All statistical procedures
were performed using the BioStat software [41].
Results
Expression of RBSP3, NPRL2 and RASSF1A genes in lung
tissues of healthy donors
Genomic structure and location of primers and probes
is shown in Figure 1.
It is known that normally looking cells surrounding
tumors can already harbor genetic and epigenetic
changes compared to the cells isolated from the same
tissue from healthy individuals. Therefore we decided to
check expression of these 3 genes in samples obtained
from healthy donors and in biopsies of “normal”
(matched) control samples obtained from patients with
NSCLC. The mRNA levels were measured in lung tis-
sues from healthy donors using different reference sam-
ples. RNA pool isolated from lung tissues of 10 healthy
donors was used in one set of experiments and in
another test the same samples were examined against
RNA pool isolated from adjacent to tumor “normal” tis-
sues of 30 NSCLC patients. The GAPDH was used as a
reference gene and its expression did not vary more
than 2-fold in all samples examined. Very similar results
were obtained for target genes in both experiments. We
concluded that expression of all three genes did not
significantly vary (R = 1.5 ± 0.5) in normal lung tissues
from healthy donors and patients with NSCLC
("normal” matched controls).
Expression of three TSGs in primary NSCLC - AC and SCC
The results of mRNA level quantification for three
genes and statistical analysis are shown in Figures 2 and
3a n dT a b l e3 .T h ev a r i a b i l i t yo fGAPDH and RPN1
mRNA was less than 2-fold in studied samples, there-
fore in this study we considered significant greater than
or equal to 2-fold decrease of target genes expression.
RBSP3
Significant (from 2 to 94-fold) decrease of the mRNA
level (LD) was observed in 85% (50 of 59, P < 0.001) of
all NSCLC cases. Frequency of mRNA decrease (FD)
was high in both AC (78%) and SCC (88%). Interestingly
at Stage I of the SCC cases expression of RBSP3 was
down-regulated already in 100% cases and only in 71%
of AC samples (Table 3). On the other hand the ten-
dency of more severe deregulation of RBSP3 transcrip-
tion during tumor progression was more evident for AC
cases: in average a 3-fold declined expression in 70% of
cases without metastases and a 6-fold in 88% of samples
with metastases. The same was correct for cases at
Stage I (LDav =3 ,F D=7 1 % )a n dS t a g eI I I( L D av =6 ,
Figure 1 Schematic representation of the RBSP3 (A), NPRL2/G21/NPR2L/TUSC4 (B), and RASSF1A (C) genes. Exon-intron structure of
known mRNAs is shown. Coding and non-coding mRNA regions are depicted by dark and light grey boxes, respectively. Primers and probes
designed for qPCR are shown by arrows and boxes above mRNAs. A. RBSP3 (3p21.3, AP20 region). Forward primer crossed the 1
st/2
nd exons
boundary, reverse primer and probe were located in the 2
nd exon. B. NPRL2 (3p21.3, LUCA region): Forward primer crossed the 5
th/6
th exons
boundary, reverse primer crossed the 6
th/7
th exons boundary, probe was located in the 6
th exon. C. RASSF1A (3p21.3, LUCA region): Forward
primer crossed the 1
st/2
nd exons boundary that provides specificity to isoforms A and E. Reverse primer crossed the 2
nd/3
rd exons boundary that
provides specificity to isoforms A, B and D. Combination of forward and reverse primers provided specificity to isoform A only. Probe was
located in the 2
nd exon.
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Page 5 of 13Figure 2 The relative expression levels of RBSP3, NPRL2/G21 and RASSF1A genes in AC and SCC. The mRNA level of each target gene
was normalized by that of the reference gene GAPDH. Data for ADC and SCC were presented according to cancer progression stages and to
the presence of metastases.
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Page 6 of 13FD = 100%). Spearmen’s coefficient of reverse correla-
tion (rs) between tumor Stages (I, II, III) and expression
R values was 0.36 (P = 0.2, i.e. non-significant).
NPRL2
Significant decrease of LD (from 2 to 100-fold) was
seen in 73% (43 of 59, P < 0.001) of all NSCLC cases.
Down-regulation of NPRL2 was more significant in SCC
c o m p a r e dt oA C :9 - f o l da n d8 5 %v s .4 - f o l da n d4 4 % ,
respectively, P = 0.002 (see Table 3). No expression was
found in 12% (5 of 59) of SCC cases. The FD was com-
parable in SCC cases with metastases and without (82%
and 88%, respectively). However FD in AC samples
without metastases was less than with metastases (20%
against 75%; P = 0.08). Again at Stage I of the SCC
cases expression of NPRL2 was down-regulated already
in 100% cases and in AC only 14% samples showed
decreased expression. The tendency of more frequent
decrease of NPRL2 mRNA level with tumor progression
was seen only for AC cases, where Spearmen’sc o e f f i -
cient of reverse correlation (rs) between tumor Stages
(I, II, III) and expression R values was 0.47 (P = 0.06).
Eighty three percent of AC cases had decreased expres-
sion at Stage III as compared to 14% at Stage I.
RASSF1A
Significant decrease of LD (from 2-fold to 57-fold) was
detected in 67% (24 of 36, P < 0.01) of all NSCLC cases,
including 64% of AC and 68% of SCC samples (Figure
2, Table 3). More severe deregulation of RASSF1A
expression was observed during tumor progression both
in AC and SCC. Spearmen’s coefficient of reverse corre-
lation (rs) between tumor Stages (I, II, III) and R values
was 0.54 (P = 0.05) for AC. Statistically significant
decrease of LDav and increase of FD was observed in
AC for patients with metastases and without (7-fold and
100% vs. 4-fold and 29%, P < 0.05). The same tendency
was seen for LDav and FD in SCC cases with and with-
out metastases: namely, 6-fold and 81% vs. 4-fold and
33%, respectively; P = 0.196. Moreover an average
decrease of RASSF1A mRNA (LDav)i nS C Ca tS t a g eI
was 4-fold and at Stage III it was already 7-fold.
FD increased for both SCC (33% vs. 82%) and AC
(29% vs. 100%) during tumor progression from Stage I
to Stage III.
Surprisingly a 3-to-4 fold increase of mRNA level of
two genes - NPRL2 and RASSF1A was found for several
AC samples at Stage I (Figure 2, samples 1, 3, 5). These
Figure 3 Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G2,1 and RASSF1A in primary non-small cell
lung cancer (AC and SCC). The data were for the same 36 primary tumor samples as the data presented in Figure 2. The mRNA level of each
target gene was normalized by those of two reference genes GAPDH and RPN1.
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samples 2, 4, 9, 10 and others that displayed low degree
of differentiation and significant decrease of NPRL2 and
RASSF1A.S o m eo ft h e ms h o w e ds oh i g hd e g r e eo fa n a -
plasia that the epithelial phenotype was almost undetect-
able. These undifferentiated cells were highly malignant
and showed the strongest decrease of NPRL2 and
RASSF1A expression.
Simultaneous down-regulated expression of three genes
in the same tumor samples
As expression of all three target genes was frequently
decreased in the same NSCLC samples we tested the
probability that this decrease was not random. To do
this we used 36 NSCLC samples and two control refer-
ence genes GAPDH and RPN1 (Figure 3, Table 4).
Results demonstrated that this simultaneous down-regu-
lation was very frequent and statistically valid: all three
genes had reduced expression (≥2) in 39% (P < 0.001) of
NSCLC specimens (36% in AC and 41% in SCC). Simul-
taneous decreased expression of RBSP3 and NPRL2 was
observed in 61% of cases and for RBSP3 and RASSF1A
this occurred in 50%. In the case of NPRL2 and
RASSF1A simultaneous down-regulation was detected in
44% of tumors (Table 4). Spearmen’s coefficient values
rs for RBSP3, NPRL2/G21, RASSF1A gene pairs were
high (0.63 - 1.0, P < 0.001) in different groups especially
in AC and SCC with metastases.
Decreased expression of RBSP3, NPRL2 and RASSF1A in
primary NSCLC can be caused by genetic and epigenetic
factors
To understand the mechanism underlying the observed
down-regulation of RBSP3 in NSCLC samples we used
qPCR to test DNA copy number changes, i.e. genetic
factors [9,10] and NotI microarrays to examine methyla-
tion i.e. epigenetic factors [39]. Methylation was
detected in 38% of AC (3 of 8) and in 80% of SCC (8 of
10) cases with decreased expression of RBSP3. Deletions
were detected in 25% of AC samples and in 30% of SCC
tumors (Table 5). Both methylation and hemizygous
deletions were observed in two SCC specimens. Methy-
lation or/and deletions of RBSP3 were detected in 63%
of AC and in 90% of SCC cases. The data suggested
that both genetic and epigenetic mechanisms are impor-
tant for transcriptional inactivation of RBSP3 in NSCLC.
Using NotI microarrays we cannot test methylation of
NPRL2 and RASSF1A promoters because they don’t
contain NotI sites. However we can check genes
SEMA3F and GNAI2 that are located in the same LUCA
sub-region as NPRL2 and RASSF1A.W et e s t e dh o w
often deletions and methylations occurred in the same
NSCLC sample at both LUCA and AP20 sub-regions
and found that this occurred in 58% of all studied cases
(15 of 26). Thus, most likely both genetic and epigenetic
mechanisms are responsible for simultaneous down-reg-
ulation of expression of these three genes.
Table 3 The frequency of mRNA decrease (FD) and the average level of mRNA decrease (LDav)
Clinical stage/Groups Frequency (FD)
a and level of mRNA decrease (LDav)
b
RBSP3
(59 tumors)
NPRL2
(59 tumors)
RASSF1A
(36 tumors)
AC SCC AC SCC AC SCC
IF D
LDav
*71 (5/7)
*3 (2 – 6)
*100 (11/11)
*7 (2 – 23)
14 (1/7)
2
*100 (11/11)
*7 (2 – 100)
29 (2/7)
4( 3– 5)
33 (2/6)
4( 2– 8)
II FD
LDav
*60 (3/5)
*5 (2 – 9)
*79 (15/19)
*4 (2 – 11)
40 (2/5)
6( 5 –7)
*74 (14/19)
*9 (2 – 100)
100 (1/1)
6
80 (4/5)
5( 2– 8)
III FD
LDav
*100 (6/6)
*6 (2 – 26)
*91 (10/11)
*8 (2 – 94)
*83 (5/6)
*4 (2 – 7)
*91 (10/11)
*10 (2 – 100)
*100 (6/6)
*7 (3 – 21)
*82 (9/11)
*7 (2 – 57)
Group without metastasis FD
LDav
*70 (7/10)
*3 (2 – 6)
*88 (21/24)
*5 (2 – 23)
*20 (2/10)
*4 (2 – 7)
*88 (21/24)
*10 (2 – 100)
29 (2/7)
4( 3– 6)
33 (2/6)
4( 2– 8)
Group with metastasis FD
LDav
*88 (7/8)
*6 (2 – 26)
*88 (15/17)
*7 (2 – 94)
*75 (6/8)
*4 (2 – 7)
*82 (14/17)
*8 (2 – 100)
*100 (7/7)
*7 (3 – 21)
*81 (13/16)
*6 (2 – 57)
Total FD
LDav
*78 (14/18)
*4 (2 – 26)
*88 (36/41)
*6 (2 – 94)
*44 (8/18)
*4 (2 – 7)
*85 (35/41)
*9 (2 – 100)
*64 (9/14)
*6 (3 – 21)
*68 (15/22)
*6 (2 – 57)
a – Frequencies of expression decrease are shown as percentages. The number of cases with decreased expression and all tested samples are shown in
parentheses.
b – Level of expression decrease in tumor samples is shown in n-fold relative to expression in normal controls
* – cases when decrease of target gene expression (FD and LDav) in tumor samples relative to normal controls was statistically valid according to the non-
parametric Wilcoxon test (P ≤ 0.05 -0.001)
Bold font designates cases when: (i) FD and LDav for NPRL2 genes was more strongly pronounced in SCC than in AC samples according to the Mann -Whitney
test (P = 0.002) and (ii) the difference of the FD and LDav for RASSF1A gene was statistically valid during AC progression according to the Mann -Whitney test
(P < 0.05)
Underlined italics highlights positive tendency of FD and LDav differences of RBSP3, NPRL2 and RASSF1A genes during progression (AC and SCC respectively)
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Several candidate TSG from the 3p21.3 AP20 and
LUCA sub-regions were examined in the gene inactiva-
tion test, GIT [2,12,13,16,34,42,43]. The test is based on
the functional inactivation of analyzed genes that can be
achieved in different ways: by mutation, deletion, methy-
lation etc. According to these results, at least three
g e n e sc a nn o wb ec o n s i d e r e da sb o n af i d el u n gT S G :
NPRL2 and RASSF1A from LUCA and RBSP3 from
AP20 sub-regions [12,13,16].
Earlier the decrease of RBSP3 expression was shown
in SCLC, NSCLC, cervical, renal, breast, ovary, leukemia
cell lines and primary tumors by Northern blot analysis,
RT-PCR and qPCR [12,44-46]. The decrease or absence
of NPRL2/G21 expression was detected in some SCLC,
NSCLC and renal cancer cell lines using Northern blot
analysis [6,16]. The decrease or absence of RASSF1A
expression was found in SCLC, NSCLC and many other
tumors and cancer cell lines [see [24,27,28]].
It was reported that promoter methylation was the
main mechanism of RASSF1A loss of expression in lung
cancer (see Introduction). Homozygous deletion of 3’-
part of NPRL2 gene and rare mutations were found in
NSCLC and SCLC cell lines [6,16]. There are no methy-
lation data explaining the loss of RBSP3 expression in
lung cancer. However frequent deletions and mutations
were reported [10,12,15]. In some leukemia cell lines
(up to 98%) and acute leukemia lymphoma blood sam-
ples (24%) methylation of the promoter region of RBSP3
was reported [44]. Methylation (up to 26%), deletions
and decreased expression of RBSP3 were significantly
associated with poor prognosis of cervical cancer [45].
Thus, inactivation of RBSP3 might be one of the early
events in cervical carcinogenesis.
Loss of heterozygosity and quantitative real-time PCR
demonstrated that aberrations in both LUCA and AP20
sub-regions occurred simultaneously in the same tumor
with high probability. Thus, it was suggested that aber-
rations in both LUCA and AP20 sub-regions could be
linked [9,10]. Indeed, homozygous deletions in both
regions often occur in the same tumor (P < 3 × 10
-7).
The estimation of possible interdependency between all
aberrations in the loci NLJ-003 (AP20) and NL3-001
(LUCA) as different events was carried out using a per-
mutation test for four types of cancers: lung, renal,
breast and ovarian. This test also revealed a significant
correlation between different aberrations in these two
loci (P < 10
-6) .T h es a m er e s u l t sw e r eo b t a i n e du s i n g
Pearson correlation for numeric values of copy number
changes of these loci. Indeed, proteins RBSP3 and
RASSF1A could collaborate in cell cycle arrest: RASSF1A
by inhibiting cyclin D1 [32] and RBSP3 by dephosphory-
lating pRB [12]. Thus functional collaboration of these
two genes could result in activation of the RB1 gene.
In this study we tested the hypothesis that TSG in
AP20 and LUCA regions were not only deleted but
their expression could also be simultaneously down-
regulated in NSCLC. This suggestion was indirectly sup-
ported by other studies that showed that genes over
large chromosomal regions could be regulated in a coor-
dinated fashion [33,47-49].
First we found that expression of all three genes is
rather uniform in lung samples isolated from healthy
donors and from normally looking lung samples obtained
from NSCLC patients ("normal” matched control sam-
ples). Thus adjacent morphologically normal tissues from
the patients can be used as paired reference controls to
tumor samples. In the study two parameters were ana-
lyzed - the level of mRNA decrease and frequency of
mRNA decrease in two major NSCLC histological sub-
t y p e s( A Ca n dS C C )a n dt h e i rs u b g r o u p sw i t hd i f f e r e n t
characteristics such as clinical Stage, grade, tumor locali-
zation, presence of metastases and others. Although both
parameters reflect deregulation of gene expression, they
are not randomly but rather functionally related.
Expression analysis of the three genes revealed the
following main features.
1. Expression of the three studied TSG was signifi-
cantly decreased in NSCLC: 85% for RBSP3, 67%
for RASSF1A and 73% for NPRL2 (P < 0.001). It was
statistically valid both for SCC and AC.
Table 4 The frequencies of simultaneous mRNA level
decreases (FD) for the combination of genes RBSP3,
NPRL2/G21 and RASSF1A in different groups
Groups
aFD, (%)
RBSP3
/NPRL2/
G21
RBSP3/
RASSF1A
RASSF1A/
NPRL2/G21
RBSP3/
NPRL2/G21
/RASSF1A
AC I 14 (1/7) 14 (1/7) 0 (0/7) 0 (0/7)
II+III 71 (5/7)
rs= 0.88
100 (7/7)
rs= 0.88
71 (5/7)
rs= 0.74
71 (5/7)
Total 43 (6/14) 57 (8/14) 36 (5/14) 36 (5/14)
SCC I 67 (4/6) 17 (1/6) 33 (2/6) 17 (1/6)
II+III 75 (12/16)
rs= 1.00
56 (9/16)
rs= 0.88
56 (9/16)
rs= 0.88
50 (8/16)
Total 73 (16/22)
rs= 0.94
45 (10/22)
rs = 0.74
50 (11/22)
rs = 0.69
41 (9/22)
NSCLC I 38 (5/13) 15 (2/3) 15 (2/3) 8 (1/13)
II+III 74 (17/23) 70 (16/23) 61 (14/23) 57 (13/23)
Total 61 (22/36)
rs = 0.72
50 (18/36)
rs = 0.68
44 (16/36)
rs = 0.63
39 (14/36)
aNumber of cases with reduced mRNA level/to all cases is shown in
parenthesis
bGroup I without metastases, group II+III – with metastases
cThe rs are the Spearmen’s coefficient values of rank correlation. Bold
designates the highest correlations between pairs of genes. P < 0.001 in all
groups
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Page 9 of 132. Down-regulation of the three genes was already
evident at Stage I of NSCLC samples. Statistically
significant down-regulation of both NPRL2 and RBSP3
was seen in 100% cases at Stage I of SCC.
3. The degree and frequency of the expression decrease
for all three genes was more strongly pronounced in SCC
than in AC samples (see Table 3). This difference was
statistically valid in the case of NPRL2 (P = 0.002).
4. All studied genes were involved in progression of
AC. The tendency of more severe expression down-regu-
lation of the RBSP3 was evident during tumor progres-
sion of AC with respect to FD and LD (70% and 3-fold in
cases without metastases in contrast to 88% and 6-fold
decrease in cases with metastases, P = 0.13). For NPRL2,
this tendency was also seen only for AC - 83% of cases
had decreased expression at Stage III compared to 14% at
Stage I and in 75% of AC cases with metastases vs. 20%
of cases with metastases, P = 0.08, see Table 3). Expres-
sion of RASSF1A revealed the most strongly pronounced
correlation between decrease of expression (FD and LD)
and tumor progression both in SCC and AC. For exam-
ple, difference in FD values was obvious between cases
with and without metastases. For SCC cases this differ-
ence was 33% vs. 81% (P = 0.196) and for AC it was even
more sharp, 29% vs. 100% (P < 0.05).
5. Expression of RBSP3 and RASSF1A was most ser-
iously affected in respect to FD. For RBSPS3 it was
detected in 85% of all NSCLC cases and for RASSF1A in
67%. However, regarding LD, the expression of NPRL2
was most strongly inhibited (LDav = 8), while RBSP3
showed weaker inhibition (LDav = 5).
6. Preliminary data suggested that no statistically sig-
nificant difference was observed in cases with relation to
age, smoking history and other cytological and patholo-
gical characteristics.
7. NotI microarrays and qPCR on genomic DNA we
tested for possible mechanisms of the declined expres-
sion of RBSP3 in NSCLC. The data suggested that both
genetic and epigenetic mechanisms were important for
transcriptional inactivation of RBSP3 in NSCLC. Alto-
gether deletions were detected in 25% of AC samples
and in 30% of SCC patients. Methylation of RBSP3 was
detected in 38% of AC and in 80% of SCC cases. With
NotI microarrays we also tested how often LUCA
(NPRL2 and RASSF1A) and AP20 (RBSP3) regions were
deleted or methylated in the same tumor and found that
this occurred in 58% of all studied cases (18 of 26).
Thus, most likely both genetic and epigenetic mechan-
isms are responsible for simultaneous down-regulation
of expression of these three TSG.
Conclusion
The detailed analysis of mRNA expression levels of
three 3p TSG was performed in two histological
Table 5 Comparison of qPCR data and NotI-microarrays for RBSP3 gene
Sample number qPCR
bNot I-microarrays Possible reason of mRNA decrease
mRNA
decrease
aDNA
copy number
AC
1 0.39 + + deletion
2 0.15 - + methylation
4 0.29 - - another mechanism
5 0.49 + + deletion
7 0.37 - - another mechanism
11 0.12 - - another mechanism
16 0.29 - + methylation
17 0.12 - + methylation
SCC
23 0.16 - + methylation
25 0.13 + + deletion and methylation
26 0.21 - + methylation
27 0.39 + + deletion and methylation
43 0.48 - + deletion
46 0.14 - + methylation
52 0.06 - + methylation
53 0.46 - + methylation
54 0.08 - + methylation
55 0.26 - - another mechanism
a + deletion, - retention
b+ deletion and/or methylation, - no changes
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Page 10 of 13subtypes of NSCLC - AC and SCC respectively. The
most important finding was that expression of RBSP3,
NPRL2 and RASSF1A decreased in the same samples of
primary NSCLC: all 3 genes have reduced expression in
39% of cases (P < 0.05). Declined expression of RBSP3
and NPRL2 was observed in 61% of samples (P < 0.05),
RBSP3 and RASSF1A in 50% (P < 0.05), and NPRL2 and
RASSF1A in 44% (P < 0.05) of cases. RASSF1A and
NPRL2 are located in the same locus and if close locali-
zation is the reason for simultaneous decrease of expres-
sion then such decrease should be significantly less
frequent when genes from the LUCA region are com-
pared with RBSP3. However this was not the case and
thus close localization is not the main factor for simul-
taneous decrease of expression. At present expression of
many thousands of genes in NSCLC is investigated
using cDNA microarrays [50,51]. These experiments
already produced very valuable data. However, results of
different studies varied significantly. They should be
proved by independent methods and qPCR is one of the
methods of choice that allows more detailed analysis of
particular genes. This work is one of such studies. All
presented data confirm and extend our previous results
for lung, renal, breast, cervical cancers [9,10] and sup-
port the hypothesis that two TSG clusters (in AP20 and
LUCA) are very likely co-regulated by common
mechanisms.
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